Vasculitis & polymyalgia rheumatica
Efficacy and safety of upadacitinib in anti-TNF-refractory intestinal Behçet’s disease: a single-center retrospective study
Authors' conclusion
Upadacitinib represents a potential therapeutic option for patients with anti-TNF-refractory intestinal BD.
Study context
- Population
- Patients with anti-TNF-refractory intestinal Behçet's disease (BD), Peking Union Medical College Hospital BD registry, July 2024–April 202616 underwent endoscopy
- Participants
- 17 patients
- Outcome
- CR defined by a composite:
- Disease activity index incorporating global GI symptom score
- Endoscopic evaluation
- Follow-up
- Month 6
Methodological detailssingle-centre, registry-based, consecutive patients
- Single-centre
- Registry-based
- Consecutive patients
Main finding
As reported in the abstract
CR by composite disease activity index (global GI symptom score and endoscopy)
Patients with endoscopy evaluation achieving complete remission (CR) (8/16)
50.0%
Observational data: associations, not effects.
Secondary outcomes
CR of global gastrointestinal (GI) symptom score · month 6
- Patients achieving CR of global GI symptom score (13/17)
- 76.5%
Mucosal healing · month 6
- Patients with mucosal healing (8/16)
- 50%
DAIBD score, median · month 6
- Median DAIBD at baseline (IQR 45.0-80.0)
- 55.0
- Median DAIBD at month 6 (IQR 0.0-10.0)
- 0.0
- Decreased markedly
Inflammatory markers (CRP and ESR) · month 6
- Significant reductions in CRP and ESR
GC dosage
- Upadacitinib demonstrated a GC-sparing effect
Original publication
Efficacy and safety of upadacitinib in anti-TNF-refractory intestinal Behçet’s disease: a single-center retrospective study. Rheumatology (Oxford). Published 9 September 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →